The Global Hyaluronic Acid Viscosupplementation Market was valued at USD 4.5 Billion in 2024 and is projected to reach USD 7.1 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period (2024–2030). This robust growth is primarily driven by the rising global prevalence of osteoarthritis, an aging population, increasing patient preference for minimally invasive procedures, and continuous technological advancements in next-generation injectable formulations.

As the global healthcare industry pivots towards effective, non-surgical solutions for chronic joint pain, the focus intensifies on the key pharmaceutical and medical device companies that are defining the standard of care. In this blog, we profile the Top 10 Companies in the Hyaluronic Acid Viscosupplementation Industry—a mix of established market leaders and innovative specialists shaping the future of joint health management.

---

🔟 1. Sanofi (Synvisc, Synvisc-One)

Headquarters: Paris, France
Key Product Portfolio: Synvisc, Synvisc-One

Sanofi, through its acquisition of Genzyme’s biosurgery unit, is a dominant force in the viscosupplementation market. Their Synvisc and Synvisc-One products are among the most widely recognized and clinically studied hyaluronic acid (HA) injections globally, used for treating knee osteoarthritis.

Key Market Initiatives:

• Extensive clinical data supporting efficacy and safety
• Strong direct-to-consumer and physician education marketing
• Ongoing post-market surveillance and research

Download FREE Sample Report: Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

---

9️⃣ 2. Anika Therapeutics, Inc.

Headquarters: Bedford, Massachusetts, USA
Key Product Portfolio: Monovisc, Orthovisc, Cingal

Anika Therapeutics specializes in therapeutics based on hyaluronic acid. The company’s portfolio includes both single-injection (Monovisc) and multiple-injection (Orthovisc) formulations, and Cingal, the first and only corticosteroid-combined HA product approved in various international markets.

Key Market Initiatives:

• Diverse product portfolio addressing different patient needs
• Strategic focus on combination products for enhanced efficacy
• Expansion into other regenerative medicine areas

---

8️⃣ 3. Zimmer Biomet Holdings, Inc.

Headquarters: Warsaw, Indiana, USA
Key Product Portfolio: Gel-One, Euflexxa

Zimmer Biomet, a global leader in musculoskeletal healthcare, holds a significant position in the viscosupplement market. The company markets Gel-One, a single-injection, cross-linked HA, and has expanded its offerings through acquisitions, solidifying its comprehensive joint health solutions.

Key Market Initiatives:

• Integration of viscosupplements with a full suite of orthopedic solutions
• Leveraging a vast global distribution network
• Investment in regenerative medicine platforms

---

7️⃣ 4. Fidia Farmaceutici S.p.A.

Headquarters: Abano Terme, Italy
Key Product Portfolio: HYMOVIS, GO-ON

Fidia Farmaceutici is a leading international company with a strong focus on hyaluronic acid research and production. Their HYMOVIS product is a highly viscoelastic, non-cross-linked HA formulation based on a proprietary HYAFF technology, designed for intra-articular injection.

Key Market Initiatives:

• Proprietary HA production and purification technologies
• Strong presence in European and Asian markets
• Focus on high-molecular-weight HA formulations

Download FREE Sample Report: Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

---

6️⃣ 5. Seikagaku Corporation

Headquarters: Tokyo, Japan
Key Product Portfolio: Artz, Artzdispo

Seikagaku Corporation is a Japanese pharmaceutical company with a long-standing legacy in hyaluronic acid-based products. Their Artz brand is a well-established viscosupplement in Japan and other Asian markets, known for its quality and reliability.

Key Market Initiatives:

• Deep expertise in carbohydrate chemistry and HA science
• Stronghold in the Asia-Pacific osteoarthritis treatment market
• Continuous product refinement and development

---

5️⃣ 6. Ferring Pharmaceuticals (TRB Chemedica)

Headquarters: Saint-Prex, Switzerland
Key Product Portfolio: Ostenil, Ostenil Plus

Ferring Pharmaceuticals, through its subsidiary TRB Chemedica, is a key player in the European market. The Ostenil range of products includes standard and fortified HA injections, focusing on providing effective symptom relief for osteoarthritis patients.

Key Market Initiatives:

• Focus on product purity and biocompatibility
• Strategic marketing and distribution partnerships
• Commitment to research in reproductive medicine and orthopedics

---

4️⃣ 7. Bioventus Inc.

Headquarters: Durham, North Carolina, USA
Key Product Portfolio: Durolane

Bioventus is an orthobiologics company dedicated to developing and commercializing clinically proven therapies that help people heal quickly and safely. Their Durolane product is a single-injection HA treatment with a sustained-release effect, leveraging NASHA technology.

Key Market Initiatives:

• Integration of active and passive therapeutic technologies
• Focus on improving patient outcomes and reducing costs
• Strategic acquisitions to broaden the orthobiologics portfolio

---

3️⃣ 8. Croma-Pharma GmbH

Headquarters: Leobendorf, Austria
Key Product Portfolio: Suplasyn, Suplasyn 1-Shot

Croma-Pharma is a specialty pharmaceutical company with a strong focus on aesthetics and orthopedics. Their Suplasyn range of viscosupplements is designed to restore the viscoelastic properties of synovial fluid, providing pain relief and improved joint mobility.

Key Market Initiatives:

• Proprietary manufacturing processes for high-purity HA
• Strong B2B partnerships for product distribution
• Innovation in delivery systems and combination products

---

2️⃣ 9. LG Chem Ltd. (LG Life Sciences)

Headquarters: Seoul, South Korea
Key Product Portfolio: Hyruan, Hyruan Plus

LG Chem is a major South Korean chemical company whose life sciences division is a significant manufacturer of hyaluronic acid. The company produces a range of HA-based viscosupplements under the Hyruan brand, catering primarily to the Asian market.

Key Market Initiatives:

• Vertical integration from raw HA production to finished drug product
• Expansion of geographic footprint beyond Asia
• Investment in R&D for novel biologic and small-molecule drugs

---

1️⃣ 10. Meiji Seika Pharma (Tedec Meiji)

Headquarters: Tokyo, Japan
Key Product Portfolio: Adant, Artz (in specific regions)

Meiji Seika Pharma, through its joint venture and licensing agreements, is an important participant in the viscosupplementation market. The company focuses on developing and marketing pharmaceutical products, including treatments for musculoskeletal diseases.

Key Market Initiatives:

• Strategic alliances for product development and distribution
• Focus on niche therapeutic areas with high unmet needs
• Commitment to quality manufacturing standards

Get Full Report Here: Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

---

🔬 Outlook: The Future of Viscosupplementation Is Precision and Personalization

The hyaluronic acid viscosupplementation market is undergoing a significant evolution. While traditional single and multiple-injection formulations continue to serve a large patient base, the industry is increasingly focused on next-generation solutions, personalized treatment approaches, and combination therapies that promise enhanced efficacy and longer-lasting relief.

📈 Key Trends Shaping the Market:

• Development of sustained-release and cross-linked HA formulations for longer duration of action
• Growing research into combination products incorporating corticosteroids, anesthetics, or regenerative agents like platelet-rich plasma (PRP)
• Expansion of indications beyond the knee to include hip, shoulder, and ankle osteoarthritis
• Increase in regenerative medicine approaches and the exploration of bio-engineered HA products

Get Full Report Here: Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

The companies listed above are not only providing relief to millions of osteoarthritis patients worldwide—they are at the forefront of innovating the future of non-surgical joint care.